EFFECTIVENESS OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD): REAL WORLD OUTCOMES FROM THE SECOND INTERIM ANALYSIS OF THE LUMINOUS STUDY

被引：0
|
作者：
Gilhotra, Jagjit Singh [1 ,2 ]
Mitchell, Paul [3 ]
Vote, Brendan [4 ]
Lacey, Sue
机构：
[1] Univ Adelaide, Dept Ophthalmol, Adelaide, SA, Australia
[2] Queen Elizabeth Hosp, Dept Ophthalmol, Adelaide, SA, Australia
[3] Univ Sydney, Dept Ophthalmol & Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia
[4] Launceston Eye Inst, Launceston, Tas, Australia
[5] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2015年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
110
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [1] Measuring real-world visual acuity outcomes for ranibizumab and aflibercept in treatment of neovascular age-related macular degeneration (nAMD)
    Karamat, Ayesha
    O'Neill, Charles
    Corradetti, Giulia
    Lindenberg, Sophiana
    Tojjar, Jasaman
    Almidani, Louay
    Do, Giang
    Mauger, Stephanie
    Nittala, Muneeswar
    Chauhan, Devinder
    Sadda, SriniVas
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [2] One-year outcomes with ranibizumab in treatment naive patients with neovascular age-related macular degeneration: an interim analysis from the LUMINOUS™ study
    Brand, Christopher
    Lacey, Sue
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [3] Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study
    Souied, E.
    Clemens, A.
    Macfadden, W.
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95
  • [4] Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
    Holz, Frank G.
    Minnella, Angelo M.
    Tuli, Raman
    Yoganathan, Pradeepa
    Parikh, Soumil
    Hamilton, Robin
    [J]. PLOS ONE, 2020, 15 (12):
  • [5] Two Year Real World Outcomes of Ranibizumab Therapy for Neovascular Age Related Macular Degeneration (nAMD)
    Bhalla, Minak
    Muniraju, Ramu
    [J]. OPHTHALMOLOGICA, 2014, 232 : 4 - 4
  • [6] OUTCOMES OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) IN GREECE UNDER RANIBIZUMAB
    Yfantopoulos, J.
    Rouvas, A.
    Chatzaras, A.
    Xanthopoulou, P.
    Theodosiadis, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A604 - A604
  • [7] RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Results From LUMINOUS, a Global Real-World Study
    Holz, Frank G.
    Figueroa, Marta S.
    Bandello, Francesco
    Yang, Yit
    Ohji, Masahito
    Dai, Hong
    Wykrota, Halina
    Sharma, Sanjay
    Dunger-Baldauf, Cornelia
    Lacey, Sue
    Macfadden, Wayne
    Mitchell, Paul
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (09): : 1673 - 1685
  • [8] METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kim, Leah N.
    Mehta, Hemal
    Barthelmes, Daniel
    Vuong Nguyen
    Gillies, Mark C.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1418 - 1431
  • [9] Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
    Sagong, Min
    Woo, Se Joon
    Lee, Youkyung
    [J]. CLINICAL OPHTHALMOLOGY, 2021, 15 : 1995 - 2011
  • [10] Outcomes at 1 Year with Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration: Real-World Results from the LUMINOUS Study
    Mitchell, Paul
    Macfadden, Wayne
    Lacey, Sue
    [J]. OPHTHALMOLOGICA, 2016, 236 : 1 - 1
12345